san antonio roundtable, part 1: fulvestrant dose and tamoxifen duration
Published 11 years ago • 515 plays • Length 7:46Download video MP4
Download video MP3
Similar videos
-
5:50
anastrazole and fulvestrant in hormone receptor-positive breast cancer
-
9:17
san antonio roundtable, part 3: trastuzumab, bevacizumab, and angiogenesis inhibitors
-
10:55
san antonio roundtable, part 4: everolimus in clinical practice, a new cdk inhibitor
-
5:50
anastrozole and fulvestrant in hormone receptor-positive breast cancer
-
7:25
san antonio roundtable, part 2: calor trial, triple-negative breast cancer
-
1:10
faslodex抽藥
-
28:53
neoadjuvant presurgical temozolomide in glioma patients
-
3:04
12-year results of anastrozole vs tamoxifen for breast cancer prevention
-
4:30
dr. c. kent osborne previews the san antonio breast cancer symposium
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
7:25
fulvestrant in breast cancer
-
3:05
overall survival with palbociclib plus fulvestrant
-
4:51
solar-1: alpelisib plus fulvestrant for advanced breast cancer
-
7:27
introduction and exploration of fulvestrant in metastatic breast cancer
-
1:20
what are the side effects of fulvestrant faslodex
-
0:39
the first complete molecular structure of a tetraspanin: a family of elusive proteins
-
14:21
fulvestrant (faslodex) benefits, side effects, and latest research
-
4:08
dr. jeffrey lancet and dr. kenrda sweet at ash 2022
-
6:42
alpelisib plus fulvestrant for advanced breast cancer: subgroup analyses from the phase iii sola...